April 30th 2025
A seminar shares key observations and learnings from the first round of direct price negotiations.
April 29th 2025
IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.
A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug development landscape.
April 17th 2025
The interchangeability designation for Yuflyma, a biosimilar to Humira, may help to improve patient access and reduce costs.
April 9th 2025
Respective industry and government agendas could significantly reshape the US prescription drug market.
Advocacy group warns employers about the legal risks of copay accumulators
The battle between pharma and PBMs over copays intensifies
QPharma and Five Rivers Rx collaborate on DEA compliance
Five Rivers Rx’s NavigateSOM software analyzes suspicious order monitoring
Is the opioid crisis peaking?
CDC data point to a three-month decline in overdose deaths
About one-in-five pharma packages is DSCSA-compliant, say wholesalers
November 2018 serialization deadline is looming—and FDA will not provide another extension
Pfizer gets slapped for sloppy language in a copay program
$700,000 fine to benefit New York State residents
GSK reverses course on physician payments
Not compensating for speaker programs and sponsored meetings has affected marketing, says the firm
Specialty pharmacy accreditation — burden and benefit
Accreditation status is both an entry ticket and a competitive measure for specialty pharmacies to attract manufacturer attention
Veeva gains customers with its OpenData service; litigation with IQVIA drags on
The year-old-plus litigation highlights the value of customer master data
HHS begins a process of evaluating drug importation; industry demurs
FDA working group’s effort is part of a larger move to realign drug pricing policies
Dealing with state regulation of the pharma supply chain
A patchwork of regulations challenges manufacturers and distributors in the US
TraceLink rolls out its Product Information Manager, structuring serialization data-sharing
PIM will eventually forge links from manufacturer to patient
FDA approves first marijuana-derived drug, for two rare types of epilepsy
Administrator Gottlieb warns against 'the proliferation and illegal marketing of unapproved CBD-containing products with unproven medical claims'
Hu-manity.co builds out a personal-healthcare-data platform
Newly formed company will create a marketplace where individuals assert ownership of their personal data
Online pharmacies and opioids: education is the defense
Center for Safe Internet Pharmacies builds a coalition to help families; looks into the ‘dark web’
President Trump signs Right to Try bill into law
An ‘alternative pathway’ to FDA’s existing expanded access programs?
Trump’s drug-pricing speech is long on rhetoric, short on substantive action
Eagerly anticipated address avoids major policy changes while chipping away at well-recognized pricing disincentives
Guidance for VAWD® Accreditation
Learn the steps for becoming a Verified-Accredited Wholesaler Distributor®
Upgrading opioid-treatment resources remains unfinished White House business
AMA calls for more MAT; HDA calls for better sharing of suspicious-order data
White House Council builds a case for pharma pricing reform
Most proposed solutions are already in the works
TraceLInk’s lawsuit against HDA goes poof
Organizations will collaborate on a proposed GS1 standard
Senate investigation finds gaping holes in international mail security
‘Shocking’ ease of buying and obtaining delivery of opioids has implications for drug importation
Healthcare can do better for improving compounded-pharmaceutical quality
Training, guidelines and enforcement are lagging
Get ready for more-publicized recall notices from FDA
Agency plans to issue 'not yet classified' recall notices
HDA files for dismissal of TraceLink suit over DSCSA data services
TraceLink will oppose the motion
2017 drug lists: new molecular entities, drug shortages, generic targets
SAFE-BioPharma joins health-industry digital security consortium
Move unites pharma efforts with larger healthcare network
Dr Reddy’s settles with DoJ over childproof pharma packaging
$5-million settlement resolves six-year-old issue
Suspicious order monitoring of opioids again lights up investigative journalists
Washington Post and 60 Minutes question McKesson’s 2017 $150-million fine
Aggregate spend reporting: more analytics, and now a global concern
IQVIA’s eighth annual survey shows 77% of respondents go beyond compliance reporting
EMA’s new home: Amsterdam
The Netherlands wins out in the competition to move the agency from London